<DOC>
	<DOCNO>NCT00934440</DOCNO>
	<brief_summary>To identify maximum tolerable dose ass qualitative/quantitative toxicity patient advance renal cell cancer treat combination 5-azacitidine bevacizumab .</brief_summary>
	<brief_title>A Study Evaluate Effectiveness 5-Azacitidine Bevacizumab Advanced Renal Cell Carcinoma</brief_title>
	<detailed_description>In study , investigator assess progression-free overall survival patient advance renal cell carcinoma treat 5-azacitidine combination bevacizumab . Patients continue treatment either disease progression development criterion withdrawal .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Inclusion Criteria Age &gt; 18 year old ECOG Performance Status 0 , 1 2 Adequate bone marrow , liver renal function assess follow : Hemoglobin &gt; 9.0 g/dl Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 Platelet count &gt; 100,000/mm3 Total bilirubin &lt; 1.5 time ULN ALT AST &lt; 2.5 time ULN ( &lt; 5 x ULN patient liver involvement ) Creatinine &lt; 1.5 time ULN Women childbearing potential must negative serum pregnancy test perform within 7 day prior start treatment . Women childbearing potential men must agree use adequate contraception ( barrier method birth control ) prior study entry duration study . Men use adequate birth control least 3 month last administration Bevacizumab . Ability understand willingness sign write informed consent . A sign informed consent must obtain prior study specific procedure . Patients anticoagulation must INR &lt; 1.5 PT/PTT within normal limit . Patients receive anticoagulation treatment agent warfarin heparin may allow participate . For patient warfarin , INR measure prior initiation treatment monitor least weekly , define local standard care , INR stable . Must histologically cytologically confirm renal cell carcinoma metastatic ( M1 ) . Patients unresectable primary tumor ( MO ) eligible . Must measurable disease , define least 1 lesion accurately measure least 1 dimension . Soft tissue disease radiate 2 month prior registration assessable measurable disease . Soft tissue disease within prior radiation field must progress consider assessable . Xrays , scan physical examination use tumor measurement must complete within 28 day prior registration . Xrays , scan physical examination nonmeasurable disease must complete within 42 day prior registration . Patients metastatic disease resectable primary tumor deem surgical candidate may undergo resection recover surgery . At least 28 day must elapse since surgery must recover adverse effect surgery . Urine protein must screen urine analysis Urine Protein Creatinine ( UPC ) ratio . For UPC ratio &gt; 0.5 , 24hour urine protein must obtain level must &lt; 1,000mg patient enrollment . The urine protein use calculate UPC ratio must obtain within 28 day prior registration . NOTE : UPC ratio spot urine estimation 24hour urine protein excretion UPC ratio 1 roughly equivalent 24hour urine protein 1gm . UPC ratio calculate use one follow formula : [ urine protein ] / [ urine creatinine ] protein creatinine report mg/dL May receive prior immunotherapy either interferon ( IFN ) and/or Interleukin2 ( IL2 ) combination IFN/IL2 prior chemotherapy ( ie , gemcitabine capecitabine ) . Must fail least 1 prior biologic agent ( sunitinib , sorafenib , temsorlimus ) . No limit number prior therapy . At least 14 day must elapse since last treatment . Must recover adverse effect prior therapy . May receive prior radiation therapy . At least 21 day must elapse since completion prior radiation therapy . Must recover associated toxicity time registration . Pregnant nursing woman eligible potential teratogenic side effect 5azacitidine bevacizumab develop fetus nursing infant . Women men reproductive potential must agree use effective contraceptive method . Patients history allergic reaction attribute compound similar chemical biologic composition 5azacitidine bevacizumab eligible . Involvement correlative study must offer patient require . No prior malignancy allow except follow : adequately treat basal cell squamous cell skin cancer , situ cervical cancer , adequately treated Stage I II cancer patient currently complete remission , cancer patient diseasefree 2 year . Must inform investigational nature study must sign give write informed consent accordance institutional federal guideline . Exclusion Criteria Cardiac disease : Congestive heart failure &gt; class II NYHA . Must unstable angina ( anginal symptom rest ) new onset angina ( begin within last 3 month ) myocardial infarction within past 6 month . Known brain metastasis . Patients neurological symptom must undergo CT scan/MRI brain exclude brain metastasis . Patients receive prior bevacizumab eligible phase I portion study ineligible phase II study . Cardiac ventricular arrhythmia require antiarrhythmic therapy . Uncontrolled hypertension define systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg , despite optimal medical management . Known human immunodeficiency virus ( HIV ) infection chronic Hepatitis B C. Active clinically serious infection &gt; CTCAE Grade 2 . Thrombosis embolic event cerebrovascular accident include transient ischemic attack within past 6 month . Patients tumor relate IVC thrombosis eligible . Serious nonhealing wound , ulcer , bone fracture . Major surgery , open biopsy significant traumatic injury within 4 week first study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>kidney cancer</keyword>
	<keyword>renal cell</keyword>
</DOC>